ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0172

Effectiveness of mRNA COVID-19 Vaccines in Patients with Rheumatologic Conditions on Immunosuppressive Therapies

Brandon Levian1, Charlotte Botz2, Jason Chwa2, Sophie Grove2, Vignesh Ravi2, Branden Ireifej3, daniel arkfeld4, Diana Hanna2, Jenny Hu2 and Binh Ngo2, 1Keck School of Medicine, Beverly Hills, CA, 2Keck School of Medicine, Los Angeles, 3LAGMC/Keck School of Medicine, Los Angeles, CA, 4Keck Medical Center of USC, RANCHO PALOS VERDES, CA

Meeting: ACR Convergence 2024

Keywords: Anti-TNF Drugs, COVID-19, rheumatoid arthritis, risk factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Epidemiology & Public Health Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Despite extensive data supporting the effectiveness of mRNA vaccines against SARS-CoV-2 in immunocompetent individuals, their efficacy in immunosuppressed patients remains uncertain. Consequently, this study aims to assess the immune response to the SARS-CoV-2 mRNA vaccine in patients with rheumatologic diseases who are on immunosuppressive therapy.

Methods: This retrospective case series compiled data for 339 patients with rheumatologic conditions on immunosuppressants and 87 healthy controls. The most prevalent rheumatologic conditions were rheumatoid arthritis (n = 69, 20.4%), osteoarthritis (n = 53, 15.6%), systemic lupus erythematosus (n = 40, 11.8%), and psoriasis/psoriatic arthritis (n = 16, 4.7%). Data collected included patient demographics, diagnosis history, immunosuppressive medications, and anti-SARS-CoV-2 spike protein antibody titers. Antibodies against SARS-CoV-2 were measured using a commercial quantitative anti-SARS-CoV-2 spike protein antibody immunoassay (Roche).

Results: As expected, patients with rheumatologic conditions on immunosuppressants demonstrated significantly lower levels of anti-SARS-CoV-2 spike protein IgG antibodies compared to healthy controls (p< 0.05). Patients taking hydroxychloroquine (n = 66) or methotrexate (n = 29) showed significantly higher anti-SARS-CoV-2 spike protein IgG antibody titers compared to those taking mycophenolate mofetil (n = 72) (Figure 1, p< 0.05). No significant differences in antibody titers were observed among patients taking corticosteroids, azathioprine, or calcineurin inhibitors. Additionally, patients using anti-TNF agents (n = 32) and JAK inhibitors (n = 10) produced significantly higher antibody titers compared to those treated with rituximab (n = 55) (Figure 2, p< 0.05). Patients using a single immunosuppressive agent (n = 172) exhibited significantly higher antibody titers than those using two or more immunosuppressive agents (n = 167) (p< 0.05). Finally, there was no difference in antibody titers between patients receiving one or two mRNA vaccines against SARS-CoV-2 (Figure 3). However, patients who received three vaccines had a significantly higher antibody response compared to those who received one or two vaccines (Figure 3, p< 0.05). Moreover, patients receiving four or more vaccines exhibited a significantly greater response than those receiving three or fewer vaccines (Figure 3, p< 0.05).

Conclusion: This study highlights that patients with rheumatologic conditions on immunosuppressants exhibit a reduced ability to generate an immune response to mRNA vaccines against SARS-CoV-2 compared to healthy controls. Notably, those taking mycophenolate mofetil or rituximab, as well as any patient on two or more immunosuppressive agents, show an especially decreased capacity to mount an immune response. Consequently, it is advisable to minimize the number of immunosuppressants these patients are on whenever possible. Moreover, significant increases in anti-SARS-CoV-2 spike protein antibody titers are observed after three or more vaccine doses, indicating that two or fewer doses are insufficient for this immunosuppressed population.

Supporting image 1

Immunosuppressive medications versus anti-spike antibody titers. Patients taking hydroxychloroquine (n = 66) or methotrexate (n = 29) showed significantly higher anti-SARS-CoV_2 spike protein IgG antibody titers compared to those taking mycophenolate mofetil (n = 72) (p<0.05). No significant differences in antibody titers were observed among patients taking corticosteroids, azathioprine, or calcineurin inhibitors. * denotes p<0.05.

Supporting image 2

Immunosuppressive medications versus anti-spike antibody titers. Patients using anti-TNF agents (n = 32) and JAK inhibitors (n = 10) produced significantly higher anti-SARS-CoV_2 spike protein IgG antibody titers compared to those treated with rituximab (n = 55) (p<0.05). * denotes p<0.05.

Supporting image 3

Number of COVID_19 vaccines versus anti-spike antibody titers. There was no difference in antibody titers between patients receiving one or two mRNA vaccines against SARS-CoV_2. However, patients who received three vaccines had a significantly higher antibody response compared to those who received one or two vaccines (p<0.05). Moreover, patients receiving four or more vaccines exhibited a significantly greater response than those receiving three or fewer vaccines (p<0.05). * denotes p<0.05.


Disclosures: B. Levian: None; C. Botz: None; J. Chwa: None; S. Grove: None; V. Ravi: None; B. Ireifej: None; d. arkfeld: None; D. Hanna: None; J. Hu: None; B. Ngo: None.

To cite this abstract in AMA style:

Levian B, Botz C, Chwa J, Grove S, Ravi V, Ireifej B, arkfeld d, Hanna D, Hu J, Ngo B. Effectiveness of mRNA COVID-19 Vaccines in Patients with Rheumatologic Conditions on Immunosuppressive Therapies [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/effectiveness-of-mrna-covid-19-vaccines-in-patients-with-rheumatologic-conditions-on-immunosuppressive-therapies/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effectiveness-of-mrna-covid-19-vaccines-in-patients-with-rheumatologic-conditions-on-immunosuppressive-therapies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology